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Original Research Communications
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ABSTRACT
Background: Dairy products contain many nutritious components
that may benefit metabolic health. There are indications that glucose
metabolism and insulin sensitivity, which are generally disturbed in
overweight and obese individuals, may improve by increased dairy
intake. This may also affect one’s metabolic flexibility.
Objective: The aim of this study was to investigate the effects of
high compared with low dairy intake on glucose metabolism, insulin
sensitivity, and metabolic flexibility in overweight adults (aged 45–
65 y).
Methods: In this randomized intervention study, subjects consumed
a high- and a low-dairy diet [HDD (5–6 dairy portions) and LDD
(≤1 dairy portion), respectively] for 6 wk in a crossover design,
with a washout period of 4 wk. Dairy portions were 200 g semi–
skimmed yoghurt, 30 g reduced-fat (30+) cheese, and 250 mL
semiskimmed milk and buttermilk. After 6 wk, a 75-g oral-glucose-
tolerance test (13C-labeled) and a subsequent fasting challenge were
performed. Metabolic flexibility was studied by determining the
respiratory quotient (RQ) using indirect calorimetry. Fasting and
postprandial plasma concentrations of glucose and insulin were
analyzed. The dual isotope technique enabled calculation of glucose
kinetics.
Results: The study was completed by 45 overweight men and
postmenopausal women [age 58.9 ± 4.3 y, BMI 27.9 ± 1.9 kg/m2
(mean± SD)]. Fasting RQ andRQ, reflecting metabolic flexibility,
did not differ after both diets. Fasting glucose concentrations were
similar, whereas fasting insulin concentrations were lower after the
LDD (LDD: 8.1 ± 2.8 mU/L; HDD: 8.9 ± 3.3 mU/L; P = 0.024).
This resulted in a higher HOMA-IR after the HDD (P = 0.027).
Postprandial glucose and insulin responses aswell as glucose kinetics
were similar after both diets.
Conclusions: The amount of dairy intake during a 6-wk period
had a neutral effect on metabolic flexibility or postprandial glucose
metabolism in middle-aged overweight subjects. More trials are
needed to study the effects of specific dairy types and to differentiate
between metabolic subgroups. This trial was registered at trialregis
ter.nl as NTR4899. Am J Clin Nutr 2019;00:1–14.
Keywords: dairy, metabolic flexibility, glucose kinetics, over-
weight, diabetes
Introduction
High dairy intake is associated with improved metabolic
health, although depending on the amount and type of dairy
products consumed. Several cohort studies have reported that
high consumption of dairy products was associated with a
lower probability of the metabolic syndrome (1–3). Recent
observational studies and meta-analyses have shown that intake
of dairy products, such as low-fat dairy, cheese, and yoghurt,
may positively affect insulin sensitivity (IS) and reduce the risk
of developing type 2 diabetes (T2DM) (4–7). A recent dose-
response meta-analysis by Gijsbers et al. (8) suggested mainly
yoghurt to be beneficial for reducing T2DM incidence. Positive
Supported by Public-Private Partnership—TKI Agro and Food grant
TKI-AF-12104; the University Medical Center Groningen (UMCG) and
FrieslandCampina (FC) participated in this partnership.
Researchers from both FC and UMCG were involved in the design of
the study, the study was conducted at the UMCG, and data analyses and
interpretation were performed by researchers from the UMCG.
Supplemental Table 1 and Supplemental Figure 1 are available from the
“Supplementary data” link in the online posting of the article and from the
same link in the online table of contents at https://academic.oup.com/ajcn/.
Address correspondence to CE (e-mail: c.eelderink@umcg.nl).
Abbreviations used: EGP, endogenous glucose production; GC-MS, gas
chromatography–mass spectrometry; GCR, glucose clearance rate; HDD,
high-dairy diet; iAUC, incremental AUC; IFG, impaired fasting glucose;
IGT, impaired glucose tolerance; IS, insulin sensitivity; LDD, low-dairy diet;
MDA, malondialdehyde; NFG, normal fasting glucose; OGTT, oral-glucose-
tolerance test; RaE, rate of appearance of exogenous glucose; RaT, rate of
appearance of total glucose; RQ, respiratory quotient; t, time; TFA, trans fatty
acid; T2DM, type 2 diabetes mellitus.
Received August 27, 2018. Accepted for publication January 23, 2019.
First published online 0, 2019; doi: https://doi.org/10.1093/ajcn/nqz017.
Am J Clin Nutr 2019;00:1–14. Printed in USA. Copyright©American Society for Nutrition 2019. All rights reserved. This is an Open Access article distributed
under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution,







niversity Library user on 01 M
ay 2019
2 Eelderink et al.
effects may for instance be due to an increased intake of specific
micronutrients (9), amino acids (10), or fatty acids (11). However,
confirmation of these suggested beneficial metabolic effects of
dairy intake by intervention studies seems challenging. Turner
et al. (12) recently reviewed weight-stable intervention studies
(n = 10) on the effect of dairy intake on IS and reported
inconclusive results. Notably, in most dairy intervention studies
glucose control was not the primary outcome measure or was
limited to basic variables like fasting glucose and insulin (13–
15). To observe dietary-induced differences in health outcomes
in a relatively healthy population, most fasting measurements are
relatively insensitive (16). Hence, it was proposed to measure
and define health by looking at an individual’s ability to
cope with a specific challenge (“resilience”), with restoration
of homeostasis as a target resultant of various physiological
responses (16–18). Metabolic flexibility, the ability to switch
back and forth between the 2 major energy substrates—(glucose
and fat)—based on availability and need, forms a hallmark
example of such a homeostatic system (19). In general, it is
considered healthy (metabolically flexible) if there is an increased
reliance on fat oxidation during fasting and during sustained
exercise, and an increase in glucose oxidation during insulin-
stimulated conditions, such as, after feeding (20). Reduced
metabolic flexibility is a common denominator of a cluster
of diseases associated with the metabolic syndrome, including
cardiovascular diseases and diabetes, and is associated with
insulin resistance (21). The direct effect of dairy intake on
metabolic flexibility per se has rarely been studied. Dairy is
nutrient rich and is an important source ofmultiplemicronutrients
(22, 23). At a molecular level, metabolic flexibility relies on
the configuration of metabolic pathways, which are regulated
by metabolic enzymes and transcription factors, many of which
closely interact with micronutrients (24–26). It may therefore
be hypothesized that dairy consumption beneficially influences
metabolic flexibility. A study by Melanson et al. (27) found that
a 1-wk dairy-based high-calcium diet increased 24-h fat oxidation
under conditions of acute energy deficit (−600 kcal/d) compared
with a low-dairy diet, which may indicate improved metabolic
flexibility after a high-dairy intervention.
Here, we assessed the effects of 6 wk high or low dairy intake
on metabolic flexibility and glucose metabolism by challenging
the body with an oral-glucose-tolerance test (OGTT) and a
subsequent fasting challenge (for 8 h after glucose intake).
The OGTT was enriched with 13C-glucose, and a simultaneous
infusion of D-[6,6-2H2]-glucose (“dual isotope technique”)
allowed us to determine glucose kinetics: the rate of appearance
of exogenous glucose (RaE), the endogenous glucose production
(EGP), and the glucose clearance rate (GCR, rate of glucose
uptake in tissues). This provided a more complete view on
glucose handling than only measuring total blood glucose as the
resultant of these fluxes. Importantly, using GCR together with
insulin concentrations, IS could be studied inmore detail (28, 29).
Methods
Subjects
This randomized crossover intervention study (NTR4899)
was performed in middle-aged, overweight individuals [age
45–65 y, BMI (in kg/m2) ≥25 to ≤30] because of their
increased risk of developing insulin resistance and metabolic
inflexibility.
Sample size was calculated with a power calculation on our
primary endpoint [metabolic flexibility,  respiratory quotient
(RQ)], using α = 0.05, β = 0.20, and an expected SD
of 0.05, aiming to find a minimal difference of 0.03. In
anticipation of some possible dropouts (12.5%), 52 men and
postmenopausal women (+1 replacement) were included in the
study.
Subjects were mainly recruited via local advertisement (2015–
2016). A prescreening questionnaire was used to select possible
participants for a screening visit. Eligible subjects were low–
medium dairy consumers (∼1–3 servings/d) and were used
to consuming 3 main meals/d. They were not involved in
intensive sports activities more than twice a week and had a
relatively stable weight (self-reported fluctuations in body weight
<3 kg in the past 3 mo). Criteria for exclusion, as assessed
during screening, were diabetes mellitus [based on criteria
of the American Diabetes Association (30): fasting glucose
≥7.0 mmol/L, glycated hemoglobin ≥6.5% (48 mmol/mol)]
and clinically relevant abnormalities in blood lipids (total
cholesterol >8 mmol/L, triglycerides >6 mmol/L, LDL >5.7
mmol/L), hematology [Hb <8.7 mmol/L (men) or <7.5 mmol/L
(women)], or markers for liver damage (alanine aminotransferase
and aspartate aminotransferase >45 U/L) or kidney damage
(urinary albumin:creatinine ratio >30 mg/mmol). In addition,
persons using glucose- or lipid-lowering medication, or other
medication influencing glucose metabolism, such as corticos-
teroids or antipsychotic drugs, were excluded. Stable use of
blood pressure–lowering medication was allowed. Additional
exclusion criteria were blood donation or use of antibiotics
in the past 3 mo, gastrointestinal surgery or dysfunction,
or the presence of inflammatory diseases, hepatitis, or HIV
infection.
Random assignment was based on minimization (using the
softwareMinim, Stephen Evans, Patrick Royston and SimonDay,
UK) (31), to ensure minimal differences in important covariables
between groups with a different order of the intervention diet
(“High-Low” and “Low-High” groups). Subjects that were found
eligible after screening were entered into the randomization
program, using information on gender (M/F), age (45–55 y or
55–65 y), and BMI (25–27 or 28–30 kg/m2). On the day their
first intervention period started, they were informed about the
allocated start diet by the researcher.
By design it was not possible to blind neither the participants
nor the researcher and dieticians to the diet (high or low dairy).
Data processing and analysis of samples were done in a blinded
fashion, as e.g., plasma samples and raw data were labeled by
period number, not by intervention diet.
The study was conducted according to the principles of the
Declaration of Helsinki (last amended by the 64th World Med-
ical Association General Assembly, Fortaleza, Brazil, October,
2013) and in accordance with the Medical Research Involving
Human Subjects Act (WMO). Approval was obtained from the
Medical Ethics Committee of the University Medical Center
Groningen, Groningen, TheNetherlands (METc 2014/298). Each
subject gave written informed consent for the study. They
received compensation (€700 + travel costs) for their hours
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Experimental design
Each subject participated in 2 dietary interventions (high and
low dairy) for 6wk in a crossover design, with awashout period in
between of 4 wk (Figure 1A). After inclusion the subjects came
to the hospital on 6 occasions during the 16-wk study period: at
the start of each diet (weeks 0 and 10), after 3 wk for a short visit
(weeks 3 and 13), and after 6 wk of each intervention for a test
day (weeks 6 and 16). During the test day 2 challenge tests were
performed to study glucose metabolism and metabolic flexibility:
an OGTT as well as a subsequent fasting challenge (Figure
1B). During both tests, respiratory gas exchange was measured
allowing the calculation of RQ, as described in detail later. In
order to study glucose kinetics and IS, stable isotopes were used;
the OGTT was enriched with 13C-glucose and subjects received a
continuous infusion with a tracer amount of D-[6,6-2H2]-glucose.
To prevent disturbance of the measurements, the subjects were
asked to avoid the consumption of 13C-enriched foods, like cane
sugar, corn products, and pineapple, for 3 d preceding the test
day. In addition, subjects had to refrain from alcohol consumption
and strenuous exercise for ≥24 h before each study day. To
individually standardize food intake each volunteer was asked to
prepare and eat the same dinner before both test days. Subjects
fasted overnight from 2000 h, but were allowed to drink water. To
minimize variation in the 2 fasting RQ measurements performed
on the morning of the test day, subjects were instructed to come to
the research facility in themost effortless way (e.g., by car instead
of bike). After arrival [∼0730, time (t) = −150 min], a venous
catheter was inserted in each forearm: 1 for blood collection
(closed with a 3-way stopcock and flushed with NaCl solution
after bloodwithdrawal) and 1 for infusion of D-[6,6-2H2]-glucose
(98% 2H atom% excess) (Isotec). At t = −122 min, a total of
26.7 mL D-[6,6-2H2]-glucose solution (80 × 0.07 mg/kg
body weight) was infused within 2 min, and a continuous
infusion of 0.07 mg D-[6,6-2H2]-glucose per kilogram of body
weight per minute was started and maintained for 10 h, until
t = 480 min.
Two hours after the start of the glucose infusion (t = 0), the
OGTT was started. The OGTT (1.185 atom% 13C) consisted of
75 g dextrose (Natufood) dissolved in 300 mL water, with the
addition of 0.1% of [U-13C]-glucose. To increase palatability
by a slight reduction of intense sweetness, 20 drops of lemon
juice were added. The glucose drink had to be consumed within
5 min.
During the test day, subjects were on a bed in a semi–upright
position and physical activity was limited. Water (150 mL) was
provided hourly.
Dietary intervention
Each subject consumed a high-dairy diet (HDD) and a low-
dairy diet (LDD) for 6 wk. At the start of each intervention
diet, subjects were instructed by a dietician from the University
Medical Center Groningen about the dietary requirements and
restrictions. During the HDD, dairy intake consisted of 5 portions
for women and 6 portions for men, whereas during the LDD
period the subjects consumed ≤1 dairy portion/d. The amount
of dairy in both diets was within the range of habitual dairy
intake of men or women in the Netherlands [Dutch National
Food Consumption Survey 2007–2010 (32)]. The prescribed
dairy portions were 200 g semiskimmed yoghurt, 30 g reduced-
fat cheese (30+ cheese made from semiskimmedmilk containing
30% fat based on dry weight, ∼19 g fat/100 g cheese), and
250 mL semiskimmed milk and/or buttermilk (FrieslandCamp-
ina). We chose these basic “medium-fat” dairy products because
they are widely used in the Netherlands and represent the average
type of dairy used and recommended by our National Guidelines.
A standardized cup and bowl were provided. At the start of
each intervention period, subjects received a cooled bag of
dairy products (with the amount adjusted to the assigned diet).
Thereafter, participants bought the prescribed products in their
local supermarket.
During the HDD, participants were instructed to consume 1–
2 portions of cheese (maturity free of choice) and ≥2 portions
of yoghurt each day, whereas the other 1–3 dairy portions could
be chosen freely according to preference (mainly milk and/or
buttermilk). Except for the prescribed dairy products, all basic
and unsweetened, no other dairy products were allowed during
the intervention periods, except for the occasional use of small
amounts of dairy, e.g., coffee creamer, cooking cream, when
used in both intervention periods. During the washout period the
volunteers were instructed to return to their habitual diet.
The dairy products were consumed by the volunteers as part
of their daily diet. To maintain a stable body weight, caloric
intake had to be comparable, so their habitual diet had to be
adjusted accordingly, as instructed by the dietician. This was
done using a list with common “substitution products” and
their approximate caloric value (indicated by “◦” representing
∼10 kcal) as guidance. As an example, subjects could see how
many slices of bread (plus a certain topping) had a similar amount
of calories to a portion of yoghurt (with or without, e.g., cereal
or fruit). Compliance to the diet was checked and maintained by
regular contact with the dietician and/or researcher (during visits,
by phone, and via email) and by dietary assessment (using diaries,
as described next). In addition, subjects were asked to hand in the
receipts of purchased dairy products to check compliance and for
reimbursement of costs.
Dietary assessment
The subjects registered their intake of dairy portions in a
diary on a daily basis. In addition, the subjects were asked to
complete a 3-d food diary (for 2 weekdays and 1 weekend day)
on 5 occasions: before the start of the study to estimate their
habitual diet, and in the third and sixth weeks of both diets.
Food diaries were analyzed by a dietitian with the software
program EvryDietist, version 6.4.2.1 (Evry BV), which uses the
Dutch Food Composition Database 2016 to calculate energy
and nutrient intake. The information from week 3 was used to
monitor and (if necessary) adjust the subjects’ intake based on
their assigned diet and their weight during the visit at week 3, as
we aimed for a weight-stable study period.
Anthropometric measurements
Body weight was measured at each visit with the same
calibrated digital measuring scale (Seca 877, Seca GMBH), to
monitor whether a stable weight was maintained. Height was
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FIGURE 1 Schematic representation of crossover design (arrows indicate visits) (A) and test day (B). BW, body weight; OGTT, oral-glucose-tolerance
test; RQ, respiratory quotient.
a wall-mounted stadiometer (Seca 222, Seca GMBH). Waist and
hip circumference were measured at the start and end of each
intervention period, with a measuring tape with a standardized
retraction mechanism (Seca 201, Seca GMBH). Measure-
ments were performed in duplicate, without shoes and heavy
clothing.
Body composition
Body composition was estimated using a multifrequency
bioelectrical impedance analyzer (QuadScan 4000, BodyStat)
on the morning of each test day (weeks 6 and 16). Before
the measurement, the subject rested for ≥10 min on the bed
in a flat position. Following the manufacturer’s instructions,
2 electrodes were placed on the right hand and 2 on the right
foot. Although the device records impedance (Z) at 4 frequencies
(5 kHz, 50 kHz, 100 kHz, 200 kHz), the 50-kHz impedance
was used for calculations using proprietary equations. The
bioelectrical impedance analysis was used to estimate body fat
percentage and mass (in kilograms), as well as fat-free/lean mass
(in kilograms).
Physical activity
To assess the subject’s physical activity during the study
period a Baecke questionnaire (33) was completed in the sixth
week of each dietary intervention. In addition, the subjects
used a pedometer (Digi-walker SW-200, Yamax) during the 3 d
preceding the test days, to monitor physical activity. Hereby we
could check whether activity was limited and comparable before
each test day, and increase subjects’ compliance, because this
may influence the RQ results.
Metabolic flexibility
Metabolic flexibility was assessed by measuring the RQ, as an
indicator of substrate oxidation. The RQ is calculated by dividing
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RQ can have a value between 0.7 (reflecting 100% fat oxidation)
and 1.0 (reflecting 100% carbohydrate oxidation). The RQ
was determined using the indirect calorimetry system Cosmed
Quark RMR (COSMED). The ventilated hood, with a see-
through round cap around the head and face, covered subjects’
upper body. They had to lie comfortably and relaxed, and
breathe easily in and out. To prevent the volunteers from falling
asleep, they were allowed to watch a documentary or movie.
During the test day, carbon dioxide concentration in the room
was monitored (ATV-Climatrend, ATAL), because increased or
fluctuating concentrations could influence the results. To limit
variation, all RQ measurements were performed by the same
researcher.
The RQ was determined at several time points during the day
and each measurement took 30 or 40 min, depending on the
time point. Two fasting RQ measurements were performed, from
t= −90 until t = −60 min and from t = −45 until t = −15 min.
The RQ was measured during and after the OGTT at t = 5–45,
t = 65–105, and t = 125–165 min, and at t = 210–240, t = 330–
360, and t = 435–465 min.
Data from the first and last 5 min of each test were ignored,
and the remaining 20 or 30 min were divided into 10-min
periods of which a mean RQ value was calculated. This allowed
calculation ofRQ, which is an indicator of metabolic flexibility,
by subtracting the fasting RQ value (RQ before the OGTT—the
average of 2measurements) from the insulin-stimulated RQvalue
(highest value during/after the OGTT).
Sample collection
Twenty-four-hour urine.
Twenty-four-hour urine was collected by the subjects at home
the day before the test day, and kept refrigerated. The subjects
handed in the containers on the morning of the test day after
collecting the last sample, depending on the start time the day
before. The volume was calculated by dividing the weight of
the urine by 1.015. After centrifugation (2000 × g for 10
min at room temperature), aliquots were frozen in 2-mL tubes
at −80◦C.
Blood.
In the morning (t = −135), fasting blood samples were taken
for direct measurements (4.5-mL Lithium-Heparin PST II tube,
BD Diagnostics) and for separation of plasma (4-mL EDTA tube
and 4-mL Lithium-Heparin tube, BD Diagnostics). During the
test days, blood was collected into 2-mL BD Vacutainer Fluoride
tubes and 4-mLEDTA tubes (BDDiagnostics). Three basal blood
samples were collected (t = −60, t = −30, t = −15 min), then
after the OGTT, samples were taken every 15 min for 1.5 h, every
30 min for an additional 1.5 h, and then hourly until t = 480.
After centrifugation (1300 × g for 10 min at room temperature)
within 30 min, plasma aliquots were stored at −80◦C until
analysis.
Breath.
Breath samples were collected by breathing through a straw
into 10-mL Exetainer vials (Labco Limited). Two basal breath
samples were collected (t = −60, t = −5) and after the OGTT a
sample was taken every 60 min until t = 480.
Measurements in collected samples
Twenty-four-hour urine.
Twenty-four-hour urinary excretion of urea and calcium were
used as a marker for dietary intake, whereas 24-h urinary
creatinine excretion can be used to estimate muscle mass
(34) and 24-h urinary albumin excretion can give information
about kidney function. Measurements were performed on a
Roche/Hitachi Modular automatic analyzer (Roche Diagnostics,
Hitachi). In addition, we measured the urinary oxidative stress
marker 8-OHdG with an ELISA (Abcam), and malondialdehyde
(MDA) using a gas chromatography–mass spectrometry (GC-
MS) method as previously described (35).
Plasma.
Insulin concentrations were measured in plasma (EDTA) on a
Roche/Hitachi Modular automatic analyzer (Roche Diagnostics,
Hitachi). Plasma glucose concentrations were measured in
plasma (NaF) on the same analyzer using a glucose hexokinase
method.
In another aliquot (40 μL NaF plasma), derivatization of
plasma glucose to glucose penta-acetate was done to enable
analysis of isotopic enrichment of orally and intravenously
administered D-[U-13C]-glucose and D-[6,6-2H2]-glucose trac-
ers by GC-MS. The sample preparation and measurement
were recently described in detail elsewhere (36). GC-MS
analyses were performed using positive chemical ionization with
ammonia, with ions monitored for m/z ranging from m/z 408 to
414 (M0–M6). The molar percentage enrichment of [6,6-2H2]-
glucose was calculated using M0 and M2 values, whereas M0
and M6 were used to calculate 13C atom%. The obtained values
were used for calculation of glucose kinetics.
Blood lipids (total cholesterol, LDL and HDL cholesterol, and
triglycerides) and the inflammation marker high-sensitivity C-
reactive protein (limit of quantification 0.3 mg/L) were measured
on the Roche Modular analyzer directly after blood collection
(Li-Hep PST II tube, BD). MDA, as an oxidative stress marker,
was analyzed by GC-MS in heparinized plasma.
Breath.
13CO2 excretion in breath samples was measured to calculate
the oxidation rate of glucose from the OGTT. Analysis of 13C
abundance in breath carbon dioxide was performed using GC-
isotope ratio MS (Delta Plus XL; Thermo Fisher Scientific),
measuring the 13C/12C ratio against the international standard Pee
Dee Belemnite (δ13CPDB, in), as described previously (37).
Calculation of glucose kinetics
The rate of appearance of total glucose [RaT, glucose from
exogenous (OGTT) and endogenous (hepatic) sources] was
calculated from total plasma glucose concentrations and 2H-
enrichment data by using the non-steady-state equation of Steele
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that labeled and unlabeled glucose molecules showed identical
behavior. The effective volume of distribution was assumed to be
200 mL/kg and the pool fraction to be 0.75 (40). The systemic
RaE was calculated from the RaT and 13C-enrichment data, as
described by Tissot et al. (40). The EGP was calculated by
subtracting RaE from RaT (40). The GCR, which reflects the
tissue glucose uptake, was calculated as described by Schenk
et al. (41).
Incremental AUCs, fasting value, peak value, and time to
peak
To determine differences in postprandial plasma glucose,
insulin, glucose kinetics, and RQ, the 0–2 h, 0–4 h, and 0–8 h
incremental AUCs (iAUCs) were calculated using the trapezoidal
rule. The means of fasting measurements (e.g., t = −60,
−30, −15 for plasma measurements) were used as baseline
values, and areas below baseline were not included. Because
EGP is suppressed after the OGTT, the area beneath baseline
(decremental AUC) was calculated, using the mirrored graphs
of this variable. In addition, peak values and time to peak were
determined for each variable. For EGP the nadir value and time
to nadir are presented. For 13CO2 the cumulative percentage of
the dose was calculated.
Insulin sensitivity
Basal insulin resistance was estimated by the HOMA-IR, and
HOMA-β was used as an indication of β-cell function, both
calculated using fasting glucose and insulin concentrations (42).
Whole-body IS was calculated with the Matsuda index using
the mean value of glucose and insulin from t = 0 to t = 120
during the OGTT (43) and mainly peripheral IS by using GCR
(iAUC 0–2, 0–4, and 0–8 h) and insulin data [mean postprandial
values (without t = 0) over the same time period], as previously
described (28, 29).
Well-being and appetite during the test day
Subjective sensation of appetite was assessed ∼15 min before
and hourly after the OGTT with a 100-mm visual analogue scale
(0 mm stands for no appetite, 100 mm stands for big appetite)
until t = 480. At the same time points, feeling and extent of
discomfort and physical complaints such as abdominal pain,
nausea, and headache were scored hourly using a rating system
(from 0 = no complaints, to 4 = severe complaints).
Statistical analyses
Normally distributed variables are reported as mean ± SD and
nonnormally distributed variables as median [IQR]. Postprandial
data (graphs) are presented as mean ± SEM.
To determine the effect of diet, we used linear mixed-effect
models with a random intercept for subject, and with period and
diet as fixed factors. Although a washout period of 4 wk, set based
on previous reports and practical considerations, was expected
to be sufficient, an interaction term period × diet was added to
assess a possible carryover effect. A nonsignificant interaction
effect was interpreted as the absence of a carryover effect, upon
which the termwas removed from themodel. Log-transformation
was applied to normalize skewed data (inflammation and
oxidative stress markers; 24-h urinary excretion of albumin,
urea, and creatinine; step counter and beverage intake data; and
triglycerides) before their use in statistical analyses.
In secondary analyses of our primary endpoint (RQ), rele-
vant covariables (e.g., body weight, caloric intake, macronutrient
intake, fiber intake, fasting and peak insulin concentration, or
physical activity) were added to the model to adjust for possible
confounding. For a selection of outcomes (14 outcomes: fasting
RQ; RQ; fasting glucose; fasting insulin; HOMA-IR; HOMA-
β; Matsuda index; iAUC 0–4 h of glucose, insulin, RaE, EGP,
GCR and RQ; and BMI), secondary analyses were performed
adjusting for body weight. In addition, the effect of dietary
fiber and beverage intake (coffee, tea, fruit juice, and alcohol)
was taken into account in secondary analyses of fasting insulin
concentrations, HOMA-IR, and Matsuda index.
For the aforementioned selection of outcomes, we assessed
whether the effect of diet was different betweenmetabolically dif-
ferent subgroups. Therefore, additional analyses were performed
by adding an interaction term to the model [subgroup (0/1) ×
diet (0/1)]. We made subgroups based on baseline values of
HOMA-IR (above or below 2.56), BMI (above or below 28.2),
and fasting glucose [normal fasting glucose (NFG) or impaired
fasting glucose (IFG)].
Differences in dietary intake (product groups, Supplemental
Table 1) were assessed using Wilcoxon’s Signed Rank test,
because data were nonnormally distributed. All analyses were
performed using SPSS 23.0 for Windows (SPSS Inc.). A 2-sided
P value < 0.05 was considered statistically significant.
Results
Baseline characteristics
In total 7 participants dropped out of the study (owing to
problems with continuous blood collection). Because the reasons
for dropout were unrelated to the diet and there were no data
available from the test days, these subjects were excluded from
the data analysis. One of the dropouts was replaced, resulting
in 46 subjects who completed this study. Data from 1 other
participant were excluded, because of illness during the days
before the final test day. Exclusion of these dropouts did not affect
the results. A flowchart is shown in Supplemental Figure 1.
Baseline characteristics (at the start of the first dietary
intervention period) of the 45 participants with valid data are
shown in Table 1.
Dietary intake
Data from the 3-d food diaries completed in weeks 3 and 6
were averaged to get an indication of dietary intake over the
6 wk. When looking at shifts in consumption of the different
product groups during both diets (Supplemental Table 1), it was
observed that during the LDD there was an increased intake
of e.g., beverages such as coffee and tea, pastry, bread, meat
products (bread topping), and sweet bread toppings. During the
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TABLE 1 Baseline characteristics of study participants1
Characteristics
Age, y 58.9 ± 4.3
Gender
Men, n (%) 20 (44.4)
Women, n (%) 25 (55.6)
Height, cm 173.7 ± 9.4
Weight, kg 84.3 ± 9.8
BMI, kg/m2 27.9 ± 1.9
Waist circumference, cm 95.3 ± 8.7
Hip circumference, cm 107.0 ± 4.5
WHR, cm:cm 0.89 ± 0.08
Glucose, mmol/L 5.6 ± 0.5
Insulin, mU/L 11.1 ± 4.2
HbA1c, % 5.5 ± 0.3
HbA1c, mmol/mol 37.0 ± 3.4
HOMA-IR 2.8 ± 1.2
HOMA-β, % 107.1 ± 41.6
IFG (≥5.6 mmol/L), n (%) 22 (48.9)
Cholesterol, mmol/L 5.75 ± 0.96
LDL cholesterol, mmol/L 3.94 ± 0.91
HDL cholesterol, mmol/L 1.55 ± 0.37
Triglycerides, mmol/L 1.11 [0.93–1.81]
Energy intake, kcal/d 2162.7 ± 496.4
Carbohydrate intake, g/d 221.1 ± 65.8
Protein intake, g/d 81.7 ± 18.6
Fat intake, g/d 87.0 ± 24.4
Fiber intake, g/d 21.3 ± 5.1
1Values are mean ± SD, median [IQR], or n (%), n = 45. HbA1c,
glycated hemoglobin; HOMA-β, homeostasis model assessment of β cell
function; IFG, impaired fasting glucose; WHR, waist-to-hip ratio.
Table 2 contains an overview of caloric intake and nutrient
intake (per day) during the LDD and HDD. Caloric intake
was slightly higher during the HDD. The HDD resulted in a
higher intake of mono- and disaccharides (lactose), whereas
during the LDD there was a higher intake of polysaccharides
and dietary fiber (increased bread intake). During the HDD
total protein intake was increased, due to an increased amount
of animal protein, whereas plant protein intake was somewhat
decreased during the HDD compared with the LDD. Total
fat intake was similar between both diets, but during the
HDD more saturated fat was consumed. The total amount of
trans fatty acids (TFAs) in the diets was similar during both
diets.
As a consequence of high dairy consumption, calcium
intake was much higher during the HDD. Furthermore, overall
micronutrient intake (except vitamin D) increased during the
HDD, including magnesium, potassium, zinc, riboflavin, and
vitamin B-12 intake (Table 2).
Physical activity
There was no difference in physical activity during the
intervention periods based on the Baecke questionnaire (Table
3). The step counter indicated a small difference in activity (∼400
steps) on the day before the test (“day 3”) between the LDD and
HDD (P = 0.028), but no difference in the average step count
during the 3 d preceding both test days.
Body composition and anthropometric measurements
Body weight was somewhat lower after 6 wk of LDD (LDD:
83.7 ± 9.9 compared with HDD: 84.1 ± 9.9 kg; P = 0.012).
Waist and hip circumference were not different after 6 wk of
HDD and LDD (Table 4). In addition, bioelectrical impedance
analysis measurements of fat percentage and lean mass were not
significantly different between the dietary interventions, whereas
a trend towards higher fat mass after the HDD was observed
(P = 0.062).
Blood lipids
Fasting triglyceride, total cholesterol, and LDL-cholesterol
concentrations did not differ between the HDD and LDD (Table
4). HDL-cholesterol concentration was higher after the LDD
(P = 0.002). Consequently, the cholesterol:HDL ratio was lower
after the LDD (LDD: 3.84± 1.10; HDD: 3.96± 1.07;P= 0.015).
Twenty-four-hour urine excretions of albumin, creatinine,
urea, and calcium
Albumin excretion in 24-h urine was the same after both
dietary interventions. Twenty-four-hour urinary excretion of
creatinine, as a measure of muscle mass, did not differ between
the diets. Twenty-four-hour urinary excretions of urea and
calcium were higher after the HDD (Table 4), as expected owing
to increased intake of protein and calcium from the diet.
Metabolic flexibility
When comparing the HDD with the LDD, there was no
difference in mean RQ curves after the OGTT (Figure 2).
Fasting RQ, calculated based on 2 RQ measurements before the
OGTT, was similar after both diets (LDD: 0.74 ± 0.04; HDD:
0.75 ± 0.04; P = 0.560) (Table 5). In addition, the fasting
values calculated based on the 2 measurements between t = 330
and t = 480 were the same (LDD: 0.73 ± 0.02 compared with
HDD: 0.73 ± 0.02; P = 0.879). The mean of the highest RQ
value measured between t = 60 and t = 240 for each individual
was 0.87 ± 0.04 for both diets (P = 0.954). Consequently,
RQ, giving an indication of metabolic flexibility, was the same
(LDD: 0.13 ± 0.05; HDD: 0.12 ± 0.04; P = 0.707) after both
intervention periods. Linear mixed-model analyses indicated no
carryover effects. Adjustments of fasting RQ and RQ analyses
for body weight, caloric intake, macronutrient intake, fasting and
peak insulin concentration, or physical activity did not materially
change the results.
Fasting and postprandial glucose and insulin concentrations
No differences were found in fasting plasma glucose con-
centrations, time to peak, peak values, or iAUC after the diets
(Table 5). Sixteen subjects appeared to have normal glucose
values (both fasting and postprandial), whereas 29 subjects had
either impaired fasting glucose (IFG), impaired glucose tolerance
(IGT), or both. Based on the glucose values at t= 120 there were
22 subjects (49%) with IGT (≥7.8 mmol/L) after one or both
dietary periods. On average, glucose concentrations fell below
baseline around t = 180 and remained below baseline until the
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TABLE 2 Nutrient intake of 45 overweight men and women during a 6-wk high- or low-dairy diet in a crossover design1
Low-dairy diet High-dairy diet P value
Energy, kcal/d 2151.7 ± 450.7 2264.2 ± 470.9 0.015
Carbohydrates total, g/d 226.3 ± 55.3 232.0 ± 57.2 0.325
Mono- and disaccharides, g/d 93.6 ± 29.0 113.7 ± 28.4 <0.001
Polysaccharides, g/d 131.9 ± 35.9 118.1 ± 36.2 <0.001
Protein total, g/d 78.8 ± 16.7 105.9 ± 19.2 <0.001
Animal protein, g/d 43.2 ± 14.9 75.5 ± 16.0 <0.001
Plant protein, g/d 35.3 ± 9.3 30.2 ± 7.8 <0.001
Fat total, g/d 82.2 ± 20.2 84.0 ± 19.8 0.513
SFAs, g/d 25.3 ± 7.0 32.3 ± 6.8 <0.001
Trans fatty acids (TFAs), g/d 0.71 ± 0.37 0.69 ± 0.26 0.725
MUFAs, g/d 31.7 ± 8.2 28.9 ± 8.1 0.015
PUFAs, g/d 17.9 ± 6.0 14.9 ± 5.3 0.002
Dietary fiber, g/d 22.0 ± 5.4 19.6 ± 5.4 0.001
Calcium, mg/d 706.7 ± 125.2 1955.9 ± 240.9 <0.001
Magnesium, mg/d 356.9 ± 83.3 404.4 ± 73.3 <0.001
Sodium, mg/d 2602.1 ± 654.4 2636.7 ± 609.7 0.717
Potassium, mg/d 3393.9 ± 592.3 4078.9 ± 699.4 <0.001
Zinc, mg/d 10.2 ± 2.2 13.7 ± 2.5 <0.001
Riboflavin, μg/d 1.39 ± 0.48 2.58 ± 0.50 <0.001
Vitamin B-12, μg/d 4.48 ± 2.18 6.96 ± 2.24 <0.001
Vitamin D, μg/d 3.63 ± 1.39 3.05 ± 1.06 0.004
1Values are mean ± SD, n = 45. Three-day nutritional data of weeks 3 and 6 were averaged. Differences were assessed using linear mixed models.
Fasting insulin concentrations were slightly lower after the
LDD (LDD: 8.1± 2.8 mU/L; HDD: 8.9± 3.3 mU/L; P= 0.024).
Adjustments of fasting insulin for body weight; fiber intake;
and/or intake of coffee, tea, fruit juice, and alcoholic beverages
did not materially change the results. Mean postprandial insulin
concentrations were the same after both interventions (Figure 3B,
Table 5).
Glucose kinetics
No differences were observed in postprandial glucose kinetics.
Comparing the response to anOGTT after the HDD and LDD, the
mean EGP (Figure 4A), RaE (Figure 4B) as well as GCR (Figure
4C) were similar for 8 h after the OGTT. Additional outcomes
such as peak value, time to peak, and iAUC are summarized in
Table 5. The decremental AUC of EGP was somewhat higher
after the HDD, which is likely explained by the “difference”
(P = 0.051) in baseline value. In addition, a small shift in GCR
time to peak was observed (LDD: 120.4 ± 47.0 min compared
with HDD: 136.1 ± 36.7 min; P = 0.014), but no difference in
peak value of GCR, or iAUC representing the total amount of
cleared glucose in a specific time period. Linear mixed-model
analyses indicated no carryover effects. Adjustments of outcomes
for body weight did not materially change the results.
13CO2 excretion in breath
13CO2 excretion in breath, reflecting the rate of oxidation of
the 13C-labeled substrate (OGTT), was similar after both diets
(Figure 5, Table 5).
Insulin sensitivity
Due to the difference in fasting insulin values, HOMA-IR was
higher after HDD (LDD: 1.99 ± 0.72 compared with HDD:
2.21 ± 0.91; P = 0.027) and HOMA-β showed a similar
TABLE 3 Physical activity of 45 overweight men and women during a 6-wk high- or low-dairy diet in a crossover design1
Low-dairy diet High-dairy diet P value
Baecke questionnaire
Work index 2.49 ± 0.63 2.47 ± 0.65 0.667
Sport index 2.74 ± 0.54 2.75 ± 0.51 0.889
Leisure index 3.17 ± 0.51 3.27 ± 0.57 0.242
Step counter
Day 1 7624 [5075–9636] 6943 [4152–9822] 0.517
Day 2 5423 [3742–9814] 5581 [4024–8739] 0.976
Day 3 5443 [3213–8821] 5040 [3110–6357] 0.028
Mean steps/day 6621 [4312–8919] 6092 [4488–7787] 0.321
1Values are mean ± SD or median [IQR], n = 45. The step counter was used during the 3 d preceding the test day (end week 6). Differences were
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TABLE 4 Subject characteristics and 24-h urinary excretions at the end of 6 wk of low- and high-dairy diet1
Low-dairy diet High-dairy diet P value
Body composition
Height, cm 173.7 ± 9.4 173.7 ± 9.4 0.961
Weight, kg 83.7 ± 9.9 84.1 ± 9.9 0.012
BMI, kg/m2 27.7 ± 1.9 27.8 ± 1.9 0.009
Waist circumference, cm 94.9 ± 8.7 95.3 ± 8.8 0.218
Hip circumference, cm 106.1 ± 5.0 106.2 ± 5.3 0.787
WHR, cm:cm 0.90 ± 0.08 0.90 ± 0.09 0.304
Fat percentage, % 34.4 ± 8.1 34.6 ± 8.2 0.221
Fat mass, kg 28.4 ± 5.7 28.9 ± 6.3 0.062
Lean mass, kg 55.3 ± 11.7 55.6 ± 11.4 0.622
Blood lipids
Cholesterol, mmol/L 5.29 ± 0.93 5.26 ± 0.77 0.681
LDL cholesterol, mmol/L 3.55 ± 0.81 3.54 ± 0.34 0.797
HDL cholesterol, mmol/L 1.46 ± 0.38 1.40 ± 0.34 0.002
Triglycerides, mmol/L 1.02 [0.86–1.35] 1.10 [0.94–1.39] 0.066
24-h urine excretion
Albumin, mg/24 h 4.0 [2.4–6.8] 4.0 [2.3–7.0] 0.657
Urea, mmol/24 h 358.5 [279.1–437.6] 461.7 [392.9–551.3] <0.001
Creatinine, mmol/24 h 11.6 [9.9–14.8] 11.3 [9.5–14.5] 0.239
Calcium, mmol/24 h 4.1 ± 1.7 4.9 ± 2.4 0.001
Malondialdehyde, μmol/24 h 3.04 [2.55–4.12] 4.38 [3.18–6.56] 0.001
8-OHdG, μg/24 h 408.9 [353.1–478.7] 400.0 [372.3–478.5] 0.745
1Values are means ± SDs or median [IQR], n = 45. Differences were assessed using linear mixed models, a P value < 0.05 was considered statistically
significant. WHR, waist-to-hip ratio; 8-OHdG, 8-hydroxy-2-deoxyguanosine.
trend (LDD: 82.1 ± 28.8 compared with HDD: 87.2 ± 28.5;
P = 0.076).
The Matsuda index, representing a composite of both
hepatic and peripheral tissue IS, did not differ significantly
(LDD: 4.12 ± 1.75 compared with HDD: 3.84 ± 1.47;
P = 0.077), but suggested a similar trend. In addition, IS
calculated based on GCR (iAUCs) and mean postprandial insulin
concentrations were the same after both dairy interventions
(data not shown). Adjustments of IS-related outcomes for
body weight; fiber intake; and/or intake of coffee, tea, fruit

























FIGURE 2 Mean ± SEM RQ after a 13C-enriched oral-glucose-
tolerance test in overweight men and women (n= 45) after a 6-wk high-dairy
diet (•) or low-dairy diet () in a crossover design. Summary measures are
presented in Table 5; differences were assessed using linear mixed models.
RQ, respiratory quotient.
Inflammation and oxidative stress
Median high-sensitivity C-reactive protein, as a marker of
systemic inflammation, did not differ statistically between both
diets (LDD: 1.00 [0.60–2.00] mg/L compared with HDD: 1.20
[0.80–2.55] mg/L; P= 0.065). The oxidative stress marker MDA
was not different after both diets based on plasma values (LDD:
0.51 [0.45–0.65] μmol/L compared with HDD: 0.48 [0.43–0.59]
μmol/L; P = 0.196), although 24-h urinary excretion was higher
after HDD (LDD: 3.04 [2.55–4.12] μmol/24 h compared with
HDD: 4.38 [3.18–6.56] μmol/24 h; P= 0.001). The 24-h urinary
excretion of the oxidative stress marker 8-OHdGwas similar after
both dietary interventions (LDD: 408.9 [353.1–478.7] μg/24 h
compared with HDD: 400.0 [372.3–478.5] μg/24 h; P = 0.745)
(Table 4).
Appetite and feeling of discomfort
During the test days, no difference in appetite was observed in
the hours after the OGTT (data not shown), nor in complaints
such as headache, nausea, tiredness, sweating, and trembling
when comparing the HDD and LDD.
Subgroup analyses
As secondary post hoc analyses we assessed for 14 outcomes
(see the Methods section for details) whether there were any
different outcomes between metabolically different subgroups
(based on BMI, fasting glucose, and HOMA-IR). We found a
significant interaction (fasting glucose × diet) for glucose iAUC
0–4 h (P = 0.050), indicating a different effect of the dairy
diets on the glucose response between subjects with IFG and







niversity Library user on 01 M
ay 2019
10 Eelderink et al.
TABLE 5 Indexes reflecting the metabolic response after a 13C-enriched oral-glucose-tolerance test in 45 overweight men and women after a 6-wk HDD or
LDD in a crossover design1
Fasting values Peak values
Time to peak
(min) iAUC (0–2 h) iAUC (0–4 h) iAUC (0–8 h)
Glucose, mmol/L
LDD 5.5 ± 0.3 10.6 ± 1.6 61.0 ± 20.8 397.8 ± 132.7 490.2 ± 176.9 496.3 ± 177.4
HDD 5.5 ± 0.3 10.9 ± 1.7 58.0 ± 21.1 393.6 ± 132.9 484.9 ± 179.3 502.7 ± 184.8
Insulin, μU/mL
LDD 8.1 ± 2.8 115.9 ± 55.9 69.4 ± 29.5 7621 ± 3700 10,495 ± 5764 10,653 ± 5797
HDD 8.9 ± 3.3∗ 119.2 ± 59.1 72.2 ± 28.2 7927 ± 4228 11,030 ± 6255 11,135 ± 6304
RQ
LDD 0.74 ± 0.04 0.87 ± 0.04 147.3 ± 46.5 4.77 ± 3.11 16.96 ± 9.32 21.73 ± 14.75
HDD 0.75 ± 0.04 0.87 ± 0.04 146.4 ± 55.1 4.69 ± 3.11 16.16 ± 6.92 20.56 ± 9.97
RaT, mg · kg−1 · min−1
LDD 2.4 ± 0.4 7.5 ± 1.4 43.6 ± 18.2 381.0 ± 94.1 522.1 ± 115.8 523.6 ± 114.3
HDD 2.5 ± 0.3 7.2 ± 1.2 48.8 ± 22.2 366.0 ± 97.1 503.3 ± 113.3 504.2 ± 114.0
RaE, mg · kg−1 · min−1
LDD 0.0 ± 0.0 6.5 ± 1.3 49.9 ± 20.4 535.8 ± 99.4 854.8 ± 115.4 971.7 ± 119.9
HDD 0.0 ± 0.0 6.4 ± 1.2 55.5 ± 29.9 534.5 ± 103.0 862.4 ± 116.3 976.0 ± 116.8
EGP, mg · kg−1 · min−1
LDD 2.4 ± 0.4 0.32 ± 0.3 119.3 ± 60.9 155.2 ± 35.4 353.1 ± 68.9 618.8 ± 127.6
HDD 2.5 ± 0.3 0.37 ± 0.3 126.6 ± 74.1 169.5 ± 31.6∗∗ 377.2 ± 58.2∗∗ 671.5 ± 123.7∗
GCR, mL · kg−1 · min−1
LDD 2.4 ± 0.4 5.1 ± 1.2 120.4 ± 47.0 109.0 ± 81.8 271.4 ± 132.1 284.9 ± 134.5
HDD 2.6 ± 0.4 5.1 ± 1.2 136.1 ± 36.7∗ 100.0 ± 79.3 261.1 ± 133.1 273.2 ± 134.3
13CO2 (% dose/h)
LDD 0.0 ± 0.0 6.8 ± 0.8 233.3 ± 34.4 3.46 ± 0.73 15.01 ± 2.14 34.76 ± 4.38
HDD 0.0 ± 0.0 6.9 ± 0.8 228.0 ± 30.3 3.52 ± 0.73 15.32 ± 1.92 35.44 ± 4.08∗
1Values are mean ± SD, n = 45 (n = 43 for glucose kinetics). Differences were assessed using linear mixed models. RQ iAUC is based on deviating
time frames (t = 0–95, 0–230, and 0–455 min). Because EGP was suppressed after the test meals, the nadir values and time to nadir are presented. Also, the
area beneath baseline (decremental AUC) was calculated using mirrored data. For 13CO2, the cumulative values (% dose) are presented under iAUC.
∗ ,∗∗Significantly different from LDD: ∗P < 0.05, ∗∗P < 0.01. EGP, endogenous glucose production; GCR, glucose clearance rate; HDD, high-dairy diet;
iAUC, incremental AUC; LDD, low-dairy diet; RaE, rate of appearance of exogenous glucose; RaT, rate of appearance of total glucose; RQ, respiratory
quotient.
was decreased in the NFG group (441.0 ± 160.6) and increased
in the IFG group (530.9 ± 190.0) compared with the 0–4 h
iAUC of glucose after the LDD (NFG: 490.0 ± 168.6 and
IFG: 490.3 ± 189.3). Further, we found a significant interaction
(HOMA-IR× diet) for GCR iAUC 0–4 h (P= 0.008), suggesting
an opposite effect in glucose clearance between subjects with a
low and those with a high HOMA-IR index (less or more than
2.56, before intervention). After the HDD the GCR (0–4 h iAUC)
was increased in the low HOMA-IR group (293.6 ± 123.5)
and decreased in the high HOMA-IR group (223.8 ± 136.9)
compared with the GCR (0–4 h iAUC) after the LDD (low
HOMA-IR: 262.1 ± 127.9 and high HOMA-IR: 268.2 ±
151.8).
Discussion
Dairy intake is often associated with improvements in
cardiometabolic health. In this randomized crossover study we
investigated the effects of a 6-wk HDD and LDD on parameters
of metabolic flexibility and postprandial glucose kinetics after a
75-g 13C-enriched OGTT in middle-aged overweight men and
women. No differences were observed in these postprandial
outcomes between both dietary interventions.
To our knowledge, the effect of dairy intake on postprandial
metabolic flexibility per se has not yet been studied. In the present
study, we assessed metabolic flexibility using an OGTT after
6 wk of HDD or LDD. Because the flexibility of skeletal muscle
to switch between oxidizing fat and glucose is also related
to IS, glycogen stores, percentage body fat, and fitness (20),
factors like bodyweight and physical activity, as well as the
evening meal before the OGTT, were kept as stable as possible
during both dietary periods. Although instructed by dieticians to
substitute in order to have aweight-maintenance diet, the reported
difference between the HDD and the LDD was ∼100 kcal/d,
which is comparable with 1 dairy portion, and in agreement
with higher protein intake during the HDD. The current trial was
done in low–medium dairy consumers, who would have to leave
out several, often habitual, foods during the HDD in order to
consume an isocaloric diet. The difficulty of changing a habit
in eating behavior (44) is in agreement with the experiences of
several subjects during the HDD, who indicated that to reach
the goal of 5–6 dairy portions, an “extra” portion had to be
consumed before bedtime. This may explain the small difference
(∼0.4 kg) in mean body weight, consistent with a trend towards
a higher fat mass after the HDD (∼0.5 kg). A similar weight
gain was observed by Benatar et al. (45) in the group that
increased dairy intake for 1 mo. Although weight loss is known
to improve IS, the small difference in weight observed in the
present study seems unlikely to have influenced the results, as
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FIGURE 3 Mean ± SEM concentrations of plasma glucose (A) and
plasma insulin (B) after a 13C-enriched oral-glucose-tolerance test in
overweight men and women (n = 45) after a 6-wk high-dairy diet (•) or
low-dairy diet () in a crossover design. Summary measures are presented
in Table 5; differences were assessed using linear mixed models.
weight into account. In addition, muscle mass and physical
activity, which also affect IS and metabolic flexibility, remained
stable.
In general, positive findings of dairy intake related tometabolic
health may be partly due to the associations of some single
nutrients in dairy products, such as magnesium and calcium,
with IS (9). Intake of these micronutrients was higher during
the HDD, particularly calcium intake, which more than doubled
during the HDD. In addition, the type of dairy (both product
type and fat content) may also be of importance. Low-fat dairy
is often associated with beneficial cardiometabolic effects, but
there are also indications that full-fat dairy has positive effects (7,
11), despite the higher content of SFAs. Full-fat dairy is mainly
linked to IS via fatty acids such as trans-palmitoleic acid (11,
46) and it may thus be attributed to specific components in the
dairy fat. Unfortunately, nutritional data from the present study
did not differentiate between TFA intake of industrial or ruminant
origin, although their cardiometabolic effects may be different.
However, althoughwe observed no difference in total TFA intake,
it may be assumed that during HDD a larger part of TFA was
of ruminant origin (mainly from cheese), whereas during the
LDD a larger part of TFA was of industrial origin. Other studies
suggest that especially fermented dairy, and yoghurt in particular,
shows the strongest associationswithmetabolic health (8, 47, 48).
Therefore,≥2 portions of yoghurt had to be consumed during the
HDD, as well as 1–2 portions of cheese. Nevertheless, our study

































































FIGURE 4 Mean ± SEM EGP (A), RaE (B), and GCR (C) after a 13C-
enriched oral-glucose-tolerance test in overweight men and women (n = 43)
after a 6-wk high-dairy diet (•) or low-dairy diet () in a crossover design.
Summary measures are presented in Table 5; differences were assessed using
linear mixed models. EGP, endogenous glucose production; GCR, glucose
clearance rate; RaE, rate of appearance of exogenous glucose.
We did observe a slight difference in fasting insulin and
thereby HOMA-IR between the diets. Similar results were found
in a crossover study in overweight and obese individuals by
Turner et al. (49), where a 4-wk high-dairy diet (4–6 dairy
portions) increased fasting insulin and HOMA-IR compared with
high red meat intake and a control diet. In contrast, in a 12-
wk study in overweight and obese subjects an adequate dairy
diet (>3.5 servings/d) improved IS (50). Interestingly, this effect
on HOMA-IR was already visible after 1 wk, and was less
pronounced and consistent after 4 wk. A 6-mo trial in healthy
subjects consuming 4 servings of low-fat dairy per day also
improved HOMA-IR (−11%) owing to reduced fasting insulin
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FIGURE 5 Mean ± SEM 13CO2 in breath after a 13C-enriched oral-
glucose-tolerance test in overweight men and women (n = 45) after a 6-wk
high-dairy diet (•) or low-dairy diet () in a crossover design. Summary
measures are presented in Table 5; differences were assessed using linear
mixed models.
Another 6-mo intervention also found a difference in HOMA-
IR between the “milk group” (3–5 portions of dairy products)
and the control group (habitual diet), but this was due to an
unexpected increase in insulin and HOMA-IR in the control
group, whereas the “milk group” values remained stable (51).
Several other studies observed a neutral effect of dairy on fasting
glucose and insulin concentrations (45, 52, 53). A recent review
emphasized the mixed nature of results from interventions on IS
measures, evenwhen comparing the effects of weight-stable dairy
intervention trials (12). Interventions that study the effects of
dairy on whole-body IS with an additional OGTT (usingMatsuda
index), thereby going beyond measures of mainly hepatic IS, are
rather scarce. The study by Turner et al. (49) found a decrease
in IS (Matsuda) after 4 wk of high dairy, whereas a 6-mo RCT
in overweight and obese subjects comparing milk intake (1 L/d)
with other beverages found no effect (53).
We aimed for our 6-wk intervention period to be sufficiently
long to induce an effect on postprandial glucose metabolism and
IS and not too long with respect to compliance of the subjects
to the dietary obligations and restrictions. Although effects on
HOMA-IR have been observed after shorter interventions (49,
50), this period may not be long enough to affect postprandial
glucose metabolism or metabolic flexibility. Another possible
reason for a lack of effect may be related to the amount of dairy.
The large difference in dairy intake between both interventions
we aimed for was based on extremes in the amount of dairy
intake in the Netherlands [≤1 compared with 5 (women) or
6 (men) portions per day]. It is however possible that for the
general population the optimal amount of dairy intake is more
moderate or that the requirements differ for different individuals
or subgroups, as the results of our post hoc subgroup analyses
may suggest. Interestingly, the effect of dairy (especially whey
protein) on glucose metabolism and T2DM risk may depend on
the person’s specific glucokinase gene polymorphism which is
related to insulin resistance (54), indicating that some persons
may benefit more from high dairy intake than others.
The subjects in the selected age- and BMI-range were expected
to have an increased risk of the development of diabetes, but
around 35% appeared to have normal glucose values (both
fasting and postprandial), and 49% was IGT during ≥1 of
the OGTTs. Possibly, an effect of dairy intake on postprandial
glucose metabolism could be expected in subjects with a higher
BMI or age range.
Because of the large difference in dairy intake and the aim of
weight maintenance, the intake of other food products during the
LDD and HDD differed substantially. During the LDD there was
a higher intake of beverages such as coffee, tea, and fruit juice as
well as increased consumption of bread and bread toppings such
as meat products. During the HDD the intake of breakfast cereals
was increased, likely combined with the milk or yoghurt portion.
Despite this increase, dietary fiber intake was higher during the
LDD. It should be noted that these products (or their ingredients)
may also influence IS or glucose metabolism. Whole grain and
fiber intake are associated with improved IS and a lower risk of
T2DM (55). Coffee (56), tea (57, 58), and moderate alcohol (59,
60) consumption have also been associated with a reduced risk
of diabetes, which may suggest an influence of these beverages
on IS. Habitual intake of sugar-sweetened beverages and juices
is mainly associated with a greater incidence of diabetes (61),
although a recent meta-analysis of RCTs suggested a neutral
effect of 100% fruit juice on glycemic control (62). Adjustment
for differences in intake of fiber, coffee, tea, fruit juice, and
alcoholic beverages did not materially affect the results of our
study.
A strength of this study was the large difference in prescribed
dairy intake (≥4 portions/d) between the 2 intervention periods.
Furthermore, by making use of a sophisticated method using
stable isotopes to thoroughly study glucose kinetics, possible
changes in postprandial glucose metabolism underlying the total
glucose response were ruled out. The free-living situation, where
the participants could choose their own substitution diet and
had some freedom regarding the choice of milk and buttermilk,
had both advantages and disadvantages. It created a situation
which was closest to their habitual situation, increasing external
validity, but it made the dietary intervention less controlled. No
conclusions can be drawn relating a particular type of dairy to our
outcomes, as the focus was on the amount of dairy. In addition,
the use of buttermilk and reduced-fat cheese may not be common
in other countries, possibly limiting comparability with other
studies.
To conclude, in this randomized controlled crossover inter-
vention trial, the amount of dairy intake (high compared with
low) during a 6-wk period had a neutral effect on metabolic
flexibility and postprandial glucose metabolism in middle-aged
overweight subjects. More intervention trials are needed to
study the effects of dairy intake on metabolic health, possibly
making a distinction between subjects’ metabolic subgroups or
differentiating between specific types of dairy products or dairy
fat content, notably full-fat compared with low-fat dairy.
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